At a think tank meeting about autism several years ago, molecular geneticist Simon Gregory spoke with mainstream and nonconventional doctors about oxytocin, the so-called “love hormone” that some doctors were using to treat symptoms of social disconnection in children with autism.
Asking for a show of hands, Gregory was stunned to see that about a fifth of the attendees were supplying oxytocin nasal sprays to their young patients. Yet safety data were scanty, and “it was pretty evident there wasn’t any standard of care for autism,” Gregory says. “Some people were using once a day, others twice. There was no metric of successful treatment. It’s the Wild West.”
Until recently, most studies examining oxytocin treatment for autism have used small sample sizes and involved only one or two hits of the hormone. But for some parents of children on the autism spectrum, the lure of a magic mist that promises social connection, eye contact and emotional engagement is hard to resist. Although the FDA has not approved the use of oxytocin to treat autism, it is available by prescription from compounding pharmacies, and for $49.95, anyone can order a two-month supply of the oxytocin spray Liquid Trust over the Internet without a prescription.
Imagine you are Gregory. On the one hand, you see a mass migration to a trendy but unproven drug. On the other hand, some new studies lend credence to claims of oxytocin’s potential — albeit with important caveats. What do you do? Apply for grants, fast. Gregory, who directs Duke University’s Bioinformatics Workshop, is now one of a handful of scientists scrambling to chase a genie that has already left the bottle.
Oxytocin is a signaling molecule once best known for its role in “letting down” breast milk and in triggering labor and delivery. Far more than a simple “love hormone,” it is involved in many biological processes, including cardiovascular, gut and kidney function, wound healing and bone formation.
In the early 1990s, studies of monogamous prairie voles showed oxytocin helped promote lasting attachments. Since then, researchers have wondered whether the hormone could have similar “pro-social” effects in people with autism, who often struggle to understand and respond to social cues.
In a 2003 study of 15 adults with autism or Asperger’s syndrome, researchers found that a four-hour infusion of oxytocin reduced repetitive behaviors, a common characteristic of autism. A 2010 study of 13 adults with autism found oxytocin helped the participants better navigate social dynamics in a simulated ball-tossing game.
The same study found that participants shown pictures of faces were more likely to gaze at the eye region, which conveys emotional information, after a dose of oxytocin. Those results square with another recent study, presented at the Society for Neuroscience (SfN) meeting in October 2012, showing that after a dose of oxytocin, men with autism were better able to understand difficult-to-read emotions conveyed in photographs showing only people’s eyes.
Recent neuroimaging research provides more grounds for guarded optimism. Neuroscientist Kevin Pelphrey, director of Yale University’s Child Neuroscience Laboratory — and father of two children with autism — scanned the brains of children with autism after they were given a one-time dose of oxytocin.
When these children performed tasks involving pictures of people, brain regions involved with processing social information and emotional expression, sometimes collectively called the “social brain,” lit up in ways that resembled the brains of typically developing children. “We were stunned” at the extent of the response, says Pelphrey, who presented the findings at the SfN meeting.
Although the effects evaporated after a day or two, the study shows for the first time that these parts of the autistic brain “are not irretrievably broken,” Pelphrey says. “They’re just not functioning.”